Ardelyx
Clinical trials sponsored by Ardelyx, explained in plain language.
Ardelyx
ARDX
NASDAQ
Biopharmaceutical company developing treatments for gastrointestinal and kidney diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug could ease teen IBS constipation pain Results expected Sep 2026 (estimated) 🚀 Make-or-break
- New drug aims to ease chronic constipation in large trial Results expected Feb 2027 (estimated) 🚀 Make-or-break